68 citations
,
April 2014 in “Journal of Molecular Endocrinology” This review summarizes existing knowledge on androgen receptor activity in breast cancer and reports no new clinical findings, with emphasis on therapies targeting androgen signaling in specific BC subtypes.
1 citations
,
September 2020 in “Endocrinology, Diabetes & Metabolism Case Reports” This case report describes a woman with hypertension, alopecia, and other symptoms, revealing that her condition was due to ovarian hyperthecosis, highlighting the overlap of adrenal and ovarian disorders.
March 2010 in “Ejc Supplements” This article discusses the paradoxical effects of valproic acid on hair, reporting both drug-induced hair loss and the potential for hair growth when used topically, but presents no original research findings.
January 2017 in “Journal of Antivirals & Antiretrovirals” This retrospective study observed that breast cancer treatments disrupted normal blood counts and led to bone marrow suppression, highlighting the need for nutritional counseling to improve patient quality of life.
June 2026 in “Cancer Research Communications” In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.